- Home
- NBN vs BCAX Comparison
NBN vs BCAX Comparison
Compare NBN & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBN
- BCAX
- Stock Information
- Founded
- NBN 1872
- BCAX 2018
- Country
- NBN United States
- BCAX United States
- Employees
- NBN N/A
- BCAX N/A
- Industry
- NBN Major Banks
- BCAX
- Sector
- NBN Finance
- BCAX
- Exchange
- NBN Nasdaq
- BCAX NYSE
- Market Cap
- NBN 766.7M
- BCAX 670.9M
- IPO Year
- NBN N/A
- BCAX 2024
- Fundamental
- Price
- NBN $82.52
- BCAX $9.32
- Analyst Decision
- NBN Buy
- BCAX Strong Buy
- Analyst Count
- NBN 2
- BCAX 7
- Target Price
- NBN $97.50
- BCAX $29.17
- AVG Volume (30 Days)
- NBN 71.4K
- BCAX 1.4M
- Earning Date
- NBN 07-28-2025
- BCAX 08-16-2025
- Dividend Yield
- NBN 0.05%
- BCAX N/A
- EPS Growth
- NBN 23.53
- BCAX N/A
- EPS
- NBN 8.99
- BCAX N/A
- Revenue
- NBN $184,337,000.00
- BCAX N/A
- Revenue This Year
- NBN $36.62
- BCAX N/A
- Revenue Next Year
- NBN $11.46
- BCAX N/A
- P/E Ratio
- NBN $9.18
- BCAX N/A
- Revenue Growth
- NBN 24.54
- BCAX N/A
- 52 Week Low
- NBN $54.60
- BCAX $7.80
- 52 Week High
- NBN $110.35
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- NBN 45.23
- BCAX N/A
- Support Level
- NBN $80.45
- BCAX N/A
- Resistance Level
- NBN $83.19
- BCAX N/A
- Average True Range (ATR)
- NBN 1.86
- BCAX 0.00
- MACD
- NBN 0.02
- BCAX 0.00
- Stochastic Oscillator
- NBN 44.72
- BCAX 0.00
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the US. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived primarily from interest and dividends from the bank.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.